mtBiolabs’ Fast-Fail Strategy enables pharmaceutical pipelines to identify mitochondrial liabilities early in preclinical stages, helping to reduce late-stage failure and improve overall return on investment.
Historical analysis by Thomson Reuters shows that although pipelines see fewer early-stage successes, late-stage drug success is increasing, a trend attributed to the ability to “fail fast, fail cheaply”1.
Early derisking saves resources, shortens timelines, and increases the likelihood of clinical and commercial success by reducing costly late-stage failures.
Undetected mitochondrial liabilities are a leading cause of failure at late clinical stages and post-marketing. By screening for mitochondrial dysfunction preclinically, teams can identify high-risk compounds early, de-prioritize them, and advance candidates with confidence.
mtBiolab and its predecessor ICDD have offered these services since 2007. They are validated across biotech, mid-, and large pharma settings, providing actionable insights at preclinical and early clinical stages2.
The measurable benefits are striking: using the Cellesis toxicity profile, clients have achieved up to 37.3-fold ROI preclinically, with an additional 12.3-fold ROI post-launch by optimizing the marketed product relative to its competition.
Early identification of mitochondrial liabilities is a proven way to implement a fast-fail strategy, allowing teams to prioritize safe, promising candidates while reducing late-stage attrition, thus delivering measurable ROI and impact.
The Fast-Fail Strategy can be combined with companion diagnostics and other profiling platforms to provide insights on individual tolerance, cellular response, and drug safety. This ensures smarter project prioritization and supports the entire pipeline from R&D through preclinical testing.
What it is: Early-stage mitochondrial profiling to anticipate clinical tolerance. Validated since 2009 and widely used in pharma.
What it measures:
Benefits:
What it is: Bioenergetic Balance Screen to evaluate mitochondrial function and detect early toxicity. Available in HTS and dose-response studies.
What it measures :
Benefits:
What it is: Combine mitochondrial profiling with cellulomic and proteomic platforms to develop companion diagnostics.
Benefits:
All our assays are fully customizable to meet your needs.
Contact us to discuss your studyDiscover how our mitochondrial platforms support different therapeutic areas.
